Definitive Contract HHSN272201500024C
Award Date 8/7/15
Potential Completion Date 4/21/16
Potential Value $38K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Oklahoma City, OK 73104, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
5
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- The U.S. Department of Health and Human Services (HHS) National Institute of Allergy and Infectious Diseases (NIAID) awarded a $224,946 Small Business Innovation Research (SBIR) Phase I contract to Aerophase, Inc., a self-certified small disadvantaged business, for the "Treatment of Tuberculosis with Inhaled Delivery of Clofazimine." The contract is a firm-fixed-price definitive contract with a completion date of July 31, 2016. This contract supports research and development of an...
- This federal contract award was made by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Creare LLC, doing business as Creare, a small business engineering research and development company. The $591,870.00 Small Business Innovation Research (SBIR) Phase I contract is for the development of an optimized dry powder formulation and delivery system for the anti-tuberculosis drug clofazimine. The...
- This is a fixed-price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Pulmokine, Inc. for the development of "Aerosolized Delivery of Anti-Tubercular Drugs." The contract has a ceiling value of $224,960.00 and a period of performance ending on January 15, 2016. As an SBIR Phase I contract, this award supports early-stage research and...
- The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a Small Business Innovation Research (SBIR) Phase I contract to Luna Innovations Incorporated, a leading provider of advanced fiber optic sensing and measurement systems. The contract, valued at $224,997, is for the development of "INNOVATIVE ORAL FORMULATIONS FOR ANTI-TB DRUGS." This Firm Fixed Price contract has an ultimate completion date of August 25, 2017. Luna Innovations, a for-profit manufacturer, is...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Phase II contract to Luna Innovations Incorporated, a manufacturer of goods, for the development of "Innovative Oral Formulations for Anti-TB Drugs". The firm-fixed-price contract, with a potential value of $1,499,796.00, was awarded on August 28, 2018, and is set to be completed by November 30, 2020. As a...
- Via Therapeutics, LLC has been awarded a firm fixed price definitive contract valued at $3,599,145 by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases. This contract is set aside for small businesses and will support Phase I of Via Therapeutics' SBIR program efforts to develop an inhaled delivery method for clofazimine, an important drug for treating tuberculosis. The contract aligns with the agency's solicitation...
- The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $299,995 firm fixed-price contract to Via Therapeutics, LLC, a small business located in Austin, Texas. The contract is for the development of low-cost, shelf-stable, patient-adaptable clofazimine mini-tablets to treat tuberculosis in pediatric patients. This contract supports Via Therapeutics' pharmaceutical research and development efforts related to...
- This is a $224,284 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Aucta Pharmaceuticals LLC, a Minority Owned Business, For Profit Organization, Asian-Pacific American Owned, Limited Liability Company. The contract is for a "MULTIPARTICULATE DISPERSIVE TABLET FOR PEDIATRIC ANTI-TB" under the SBIR Program Phase I Action. It is a Definitive Contract and is set aside for a Total Small Business. The contract has an ultimate...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $9.85M cost-no-fee definitive contract to The Global Alliance For TB Drug Development Inc. (TB Alliance) on May 10, 2024, to develop a novel modulator targeting proteostasis for the treatment of Mycobacterium tuberculosis. The contract, which extends through April 30, 2028, will be performed in New York, NY and was competitively solicited with a posting date of January 11, 2023, and an April 11, 2023 due date. No...
- This is a SBIR Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the Department of Health and Human Services (HHS), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract has a firm fixed price of $300,000.00 and is for the development of a point-of-care test to measure antibiotic concentrations in the blood for tuberculosis (TB) treatment. Nanocomposix has prior experience providing products...